CWEB - California STD's Raging At All Time Highs And Akers Biosciences Is Working On It
California STD's Raging At All Time Highs And Akers Biosciences Is Working On It - CWEB.com
According to NPR https://www.npr.org/sections/thetwo-way/2018/05/15/611307046/california-stds-raging-at-all-time-highs-for-third-year-in-a-row
California STD cases have reached all time high. More than 300,000 cases of chlamydia, gonorrhea and syphilis were reported in 2017, a 45 percent increase from five years ago, according to data released by the California Department of Public Health.
Dr. Heidi Bauer, chief of the state health department's STD Control Branch, agreed that budget issues are part of the problem. She estimated that about $20 million in state and federal money is allocated yearly to fighting STDs — a small number in a state with nearly 40 million residents.
Bauer also suggested the rise in STDs may be a symptom of more general problems in areas such as the economically hard-hit San Joaquin Valleywhere people are struggling with poverty, substance abuse, mental health issues and homelessness.
Chlamydia is by far the most widespread of the three diseases, especially among young women under 30. Men account for the majority of syphilis and gonorrhea cases. If left untreated, the health department noted, chlamydia and gonorrhea can cause pelvic inflammatory disease and can lead to infertility, ectopic pregnancy and chronic pelvic pain.
2017 STD numbers in California
- Gonorrhea cases: 75,450
- Syphilis cases: 13,605
- Chlamydia cases: 218,710
- Congenital syphilis cases: 278
Source: CA Department of Public Health
Akers Biosciences , Inc. (AKER) a leading designer and manufacturer of rapid diagnostic screening and testing products and for its PIFA PLUSS Chlamydia Assay, the world's first rapid test for Chlamydia diagnosis using a finger stick blood sample.
ABI's PIFA PLUSS Chlamydia Assay, based on the Company's proprietary particle immunofiltration assay technology, provides results in approximately five minutes. ABI's assay was designed to make screening widely available and easy and, unlike current testing procedures, the Company's assay can be run in a wide range of settings including doctors' offices, clinics and school or university health centers.
Chlamydia trachomatis is one of the most commonly reported notifiable diseases in the US and the UK. It is among the most prevalent of all sexually transmitted diseases ("STDs ") and, since 1994, has comprised the largest proportion of all STDs reported to the United States Centers for Disease Control and Prevention ("CDC"). According to the CDC, there are an estimated 2.8 million cases annually in the US.
"Half of all Chlamydia cases in the US go undiagnosed, despite the disease being easily cured with single dose antibiotics," said Raymond F. Akers Jr., Ph.D, Executive Chairman. "Part of the reason for this is that current methodologies remain costly and time consuming and are typically analyzed in a laboratory following an endocervical or urethral swab sample collection. Our technology aims to increase the detection rate of this serious infection by making it easy for individuals to get near-instant results from a simple finger stick blood test, performed confidentially and in a convenient setting," added Dr. Akers.
ABI's PIFA PLUSS Chlamydia Assay, based on the Company's proprietary particle immunofiltration assay technology, provides results in approximately five minutes. ABI's assay was designed to make screening widely available and easy and, unlike current testing procedures, the Company's assay can be run in a wide range of settings including doctors' offices, clinics and school or university health centers.
Chlamydia trachomatis is one of the most commonly reported notifiable diseases in the US and the UK. It is among the most prevalent of all sexually transmitted diseases ("STDs ") and, since 1994, has comprised the largest proportion of all STDs reported to the United States Centers for Disease Control and Prevention ("CDC"). According to the CDC, there are an estimated 2.8 million cases annually in the US.
"Half of all Chlamydia cases in the US go undiagnosed, despite the disease being easily cured with single dose antibiotics," said Raymond F. Akers Jr., Ph.D, Executive Chairman. "Part of the reason for this is that current methodologies remain costly and time consuming and are typically analyzed in a laboratory following an endocervical or urethral swab sample collection. Our technology aims to increase the detection rate of this serious infection by making it easy for individuals to get near-instant results from a simple finger stick blood test, performed confidentially and in a convenient setting," added Dr. Akers.
Adam C. Sobel M.D., Director, Medical at Akers Bio who oversaw the clinical trial, added: "I was pleased to be involved in the trial of a test which I believe can help a large number of people -- particularly women -- who are infected with Chlamydia but who are unaware of the disease due to its typically asymptomatic nature."
"While women who are under routine gynecological care may not require this test, there are a great many more women who need a test like this at public health clinics, not-for-profit clinics, and minute clinics. This test will permit the immediate dispensing of antibiotics that will cure this disease, and prevent further spread by the infected person," added Dr. Sobel.
About Chlamydia
Chlamydia is the most commonly reported sexually transmitted disease in the U.S. Unfortunately, chlamydia infections often have no symptoms in women. Fewer than half of sexually active women are screened for chlamydia. The infections are easily cured, but dangerous if not treated.
An important complication of successful diagnosis and treatment is that chlamydia test results are typically not provided until several days after the patient visit. Since diagnosis and treatment do not occur during the same patient appointment, and because the infection is often asymptomatic, many patients are lost to followup. This is a risk not only to the patient, but to subsequent sexual partners of the patient.
One way to successfully treat the infection early and more frequently would theoretically be to diagnose infected patients and initiate therapy during the same appointment as the test sample is taken.
In the U.S., female testing for chlamydia is generally covered by the Affordable Care Act.
The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence.
The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.
The Company recently announced the engagement of two leading Independent Sales Representative (NYSEMKT:ISR) organizations to increase US sales and marketing capabilities for the Company's rapid test for heparin-induced thrombocytopenia (HIT). Investors should keep close watch on AKER.
During the FDA approval and developments the future of Akers Biosciences , Inc. (AKER) looks very positive, optimistic and huge cash flow when all licenses are approved and will be a leading indicator for the growth of the company looking forward and shareholder value.
CWEB Analyst's have Reiterates a Buy Rating for Akers Biosciences , Inc. (AKER) , and a Price Target of $8 within 12 months.
A possible Buy Out for (AKER) is strongly possible by a big pharma or competitors like
| IQV (IQV) | Iqvia Hldgs Inc Com |
.
| VRTX (VRTX) | Vertex Pharmaceuticals Inc Com |
| PTIE (PTIE) | Pain Therapeutics Inc Com New |
Read Following Article Who Will Buy Akers Biosciences Inc - CWEB.Com - cweb
Read Full Article and Videos CWEB.com - Trending News, Blog, Shopping
Comments
Post a Comment